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Abstract
Purpose To look at the evidence base for LISWT as a treatment modality for vasculogenic erectile dysfunction, focusing 
on the long-term outcomes at over 6 months following treatment.
Methods A systematic literature search was conducted utilising MEDLINE and Scopus databases from 2010 to September 
2018 by two independent reviewers. Outcome measures extracted for long-term efficacy included International Index of 
Erectile Function scores and Erection Hardness Scores. Subgroup analysis for LISWT effectiveness included age, PDE5i 
responsiveness, presence of vascular co-morbidities and smoking status.
Results The search identified eleven studies, representing a total of 799 patients. Nine studies found a significant improve-
ment in erectile function after LISWT at 6-month follow-up (median IIEF-EF improvement in 5.3 at 6 months). However, of 
five studies assessing erectile function at 12 months; two identified a plateauing of results, with three a deterioration (IIEF-
EF score changes of − 2 to 0.1 from 6 months). Erectile function did, however, remain above baseline results in all of these 
studies. Subgroup analysis revealed increasing age to reduce the response to LISWT treatment. Whilst ED severity, PDE5i 
responsiveness and co-morbidities potentially influence effectiveness, results are still inconsistent.
Conclusions LISWT may be a safe and acceptable potential ED treatment with demonstrated benefits at 6 months. There is 
some question regarding efficacy deterioration beyond this, but there is still a demonstrated benefit seen even at 12 months 
post treatment. However, quality of evidence remains low with larger multiinstitutional studies required, standardising con-
founders such as shockwave administration and oral medication use.
Keywords Erectile dysfunction · Vasculogenic impotence · Extracorporeal shockwave therapy
Introduction
Atherosclerosis of penile arteries and endothelial dysfunction, 
known as vasculogenic erectile dysfunction (ED), is the cause 
of ED in 40% of men over the age of fifty [1]. There is cur-
rently no known long-lasting or curative treatment for vascu-
logenic ED [2]. At present both AUA and EAU guidelines for Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1125 5-019-02127 -z) contains 
supplementary material, which is available to authorized users.
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the treatment of vasculogenic ED recommend initial lifestyle 
changes to address modifiable risk factors, followed by oral 
phosphodiesterase 5 inhibitors (PDE5is) as first line medi-
cal management. However, only 80% of patients respond to 
PDE5is as its mechanism of action requires both intact nerves 
and a basic level of endothelial function [3]. PDE5is are con-
traindicated in patients using nitrate therapy, so a significant 
proportion of patients with Vascular ED are forced into sec-
ond and third line treatment options [4]. Alternative treatment 
options to PDE5is include vacuum erection devices which are 
simple to use but have variable patient satisfaction rates [5], 
intracavernosal injections and topical prostaglandin E1 ana-
logues (Alprostadil). Patients unresponsive to first and sec-
ond line treatments may progress to surgical management with 
penile prosthesis [4].
The precise mechanism of action of low-intensity shock-
wave therapy (LISWT) is not fully understood; however, it is 
believed that the compression and subsequent negative pres-
sures created from the shockwave energy, the so-called cavi-
tation phenomenon, is an important factor [6]. These tensile 
forces lead to shear stress on cell membranes which have been 
shown to have the potential to treat the underlying cause of 
vascular ED by prompting increased expression of vascular 
endothelial growth factor (VEGF) [7], recruitment of perivas-
cular stem cells and recruitment of endothelial progenitor cells 
[8], resulting in neovascularisation of penile arteries. Further-
more, shockwaves may also improve nerve regeneration as 
seen in animal studies, due to a hypothesised increasing in the 
ability of injured axons to repair and Schwann cell prolifera-
tion [9] which may be useful in ED caused by neurovascular 
aetiologies. LISWT is unlike any of the currently offered treat-
ment options as it could provide men with a natural erection by 
treating the underlying pathophysiology, rather than treating 
the symptoms.
However, the evidence for its use is still debated at present, 
lacking Food and Drug Administration (FDA) approval for 
ED, and is still considered experimental by organisations such 
as the Sexual Medicine Society of North America. Addition-
ally, there has so far largely been a focus on the short-term 
efficacy of LISWT as a treatment mobility. This review of the 
literature therefore aimed to:
1. Assess the current evidence base focusing on the long-
term outcomes at over 6 months of using LISWT as a 
treatment modality for vascular ED.
2. Identify if any cohorts of patients with demonstrated 
improved long-term efficacy of treatment after LISWT
Materials and methods
This review was performed following guidelines defined in 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement [10]. The review was 
prospectively registered, PROSPERO registration number: 
CRD42018112789.
Study eligibility criteria
Original research articles utilising LISWT to treat vasculo-
genic ED, with a minimum follow-up period of 6 months 
for their cohorts, were included. Study types included were 
randomised controlled trials (RCTs) as well as prospective 
and retrospective single arm experimental studies. Exclusion 
criteria were articles not utilising either International Index 
of Erectile Function-Erectile Function Domain (IIEF-EF) or 
Erection Hardness Score (EHS) as an outcome parameter and 
studies published before 2010 (the first trial for LISWT in 
vasculogenic ED was conducted in 2010 [2]). Furthermore, 
animal studies, case studies, reviews, studies using LISWT for 
non-vasculogenic ED and studies unavailable in the English 
language were all excluded from the review.
Information sources and search
Electronic databases, MEDLINE (via PubMed) and Scopus, 
were systematically searched for research articles from Janu-
ary 2010 to September 2018. A combination of MeSH terms 
and key terms was used (‘Low-Intensity Shockwave Therapy’ 
OR ‘Pulsed Ultrasound’ OR ‘Low Intensity Ultrasound’ OR 
‘Shockwave’ OR ‘Shock wave’) AND (‘Erectile Dysfunction’ 
OR ‘ED’ OR ‘Sexual Dysfunction’). In addition, a thorough 
reference review of identified articles was conducted, to ensure 
that all relevant articles were included. The grey literature was 
searched via abstracts on Scopus and ongoing clinical trials in 
Cochrane Library and ClinicalTrials.gov, with authors con-
tacted for any available preliminary data.
Study selection
The search was conducted independently by two reviewers 
(OB and LW) to identify potentially relevant articles. Title and 
abstract screening was conducted, with full-text articles sub-
sequently screened along inclusion criteria for inclusion into 
qualitative analysis. Discrepancies between reviewers were 
discussed until 100% agreement was achieved.
Data collection and data items
Data extraction was independently conducted by two 
reviewers (OB and LW). Specific data were extracted from 
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all studies such as study type, number of participants, par-
ticipant demographics and LISWT treatment regimen. The 
primary outcome measure extracted for clinical efficacy 
included erectile function measures such as IIEF-EF or EHS 
scores after LISWT at long-term follow-up of over 6 months. 
This included both raw questionnaire score improvements, 
percentage improvements and also study defined success 
rates as per score improvements. Additionally, subgroup 
analysis of LISWT effectiveness was conducted via assess-
ment of population cohorts including age, PDE5i respon-
siveness, presence of vascular co-morbidities and smoking 
status.
Risk of bias in individual studies and across studies
The internal validity of each individual article was assessed 
using the Cochrane Risk of bias tool and with further quali-
tative analysis for randomised controlled trials and non-ran-
domised studies, respectively [11]. Non-randomised studies 
were assessed qualitatively by authors critically appraising 
the methodology, as per definitions in Online Resource 1. 
Bias across studies was assessed via the GRADE tool in 
order to provide a recommendation from our review for each 
individual outcome measure [12].
Results
Study selection
A total of 521 articles were identified through the literature 
search. Duplicate removal and initial screening excluded 434 
articles. Of the 87 full-text articles assessed for eligibility, 
a final eleven articles were included in the review (Fig. 1).
Study characteristics and result synthesis
Of the eleven articles, five were RCTs and six were non-
randomised (Table 1). Three of the RCTs were placebo-con-
trolled; the others compared two different treatment groups. 
The total number of patients investigated across all studies 
was 799 patients.
Long‑term efficacy of LISWT
Nine studies of the eleven studies [2, 13–20] found a sta-
tistically significant increase in erectile function utilising 
either IIEF or EHS scores after LISWT at over 6-month 
follow-up (median IIEF-EF score improvement from base-
line at 6 months 5.3, range 2.6–10.7). None of these studies 
demonstrated a decrease in erectile function below baseline 
post intervention (Fig. 2). However, the results from two ran-
domised, sham-controlled studies, Fojecki et al. and Olsen 
et al., did not reach the authors’ set threshold for signifi-
cance at follow-ups of over 6 months [21, 22]. The effects 
of LISWT were followed up for 24 months in one study, 12 
months in four studies and 6 months in the remaining six 
studies. When assessing studies with follow-ups of greater 
than 6 months, there appeared to be limited improvement 
in IIEF scores beyond this time period (change in IIEF-EF 
scores of between − 2 and 0.1). No studies identified an 
ongoing improvement at 12 months when compared to 6 
months with two studies demonstrating plateauing of IIEF 
scores [15, 18]. Three studies showed there was a gradual 
diminishing effect of effectiveness of LISWT beyond 6 
months; however, scores remained at above baseline erectile 
function in all cases [13, 16, 21]. The largest of these studies 
demonstrating a gradual decline was conducted by Kitrey 
et al. This prospective single-armed trial of 156 patients 
demonstrated an initial response rate of 63.5% at 1 month, 
decreasing to 42.9% at 12 months and declining to just 34% 
at 2-year follow-up.
Effect of LISWT on specific population cohorts
Subgroup analysis demonstrated conflicting findings 
between studies. Whilst the majority of studies have not 
been powered to draw conclusions based on specific sub-
groups, trends in results were seen. Age, PDE5i responsive-
ness, presence of vascular co-morbidities and smoking status 
have all been proposed to impact the efficacy of LISWT 
treatment.
Two out of three studies assessing age specifically identi-
fied a reduced effectiveness of LISWT with increasing age 
[14, 17]. These studies identified that younger age was a 
statistically significant predictor for improved treatment 
responsiveness and increasing age (> 65 years) and vascu-
lar co-morbidities shortened the duration of LISWT effects 
in comparison to younger, healthier patients. However, in 
contrast the study conducted by Bechara et al. saw no sta-
tistically significant difference in age, duration of ED or 
co-morbidities when comparing LISWT responders to non-
responders [18].
ED severity appears to have contrasting effects on 
efficacy. Whilst the study conducted by Bechara et al. 
identified that patients with severe ED responded bet-
ter to LISWT with the greatest IIEF-EF point increase, 
Kitrey and colleagues found that the duration of treatment 
effect was reduced in patients with severe ED at 24-month 
follow-up [13, 18]. Additionally, when considering dura-
tion of ED symptoms, Reisman et al. identified a negative 
effect on LISWT responsiveness with increasing dura-
tion of symptoms, finding the average ED duration to be 
3.5 years longer in LISWT non-responders than respond-
ers [20]. PDE5i response was seen to be important in a 
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single study where PDE5i responders were statistically 
more likely to receive benefit from LISWT, with longer 
duration of efficacy in this cohort [14].
Two studies assessed the effect of vascular risk fac-
tors on LISWT effectiveness. In a comparison of patients 
with at least one vascular co-morbidity (cardiovascular 
disease, hypertension, high cholesterol), to those with 
none, Reisman et al. identified lower success rates in 
those with co-morbidities (76.2% vs 93.7%, respectively) 
[20]. Smoking status was seen to negatively impact the 
success of LISWT in one study, with patients possess-
ing a smoking index of less than 20 having a statistically 
significant chance of improving erectile function (91% 
vs. 50%) [19]. Finally, the presence of diabetes demon-
strated mixed results. Whilst one study demonstrated suc-
cess rates which were 25% lower in diabetic patients, with 
shorter duration of treatment effects [20], Pelayo-Nieto 
et al. contrastingly identified that diabetic patients dem-
onstrated an improved clinical response to LISWT (62% 
vs 47%) [19].
Quality assessment of articles
There are still limited number of studies assessing long-
term follow-up after LISWT with predominantly non-
randomised trials present. Risk of bias assessment of 
randomised trials (Online Resource 2) showed the larg-
est concern to be regarding selection bias, introduced by 
attrition of study participants. Whilst higher attrition rates 
are expected due to the longer follow-up in our selected 
articles, unusually high dropout rates in some studies such 
as Srini and Fojecki et al. (over 20%) which was identified 
to be more heavily weighted towards the placebo or the 
5-week treatment group [16, 21]. This could skew results 
towards those receiving the treatment, generating false-
positive results. Additionally, the five randomised trials 
demonstrated small numbers of total participants, with 
all being single centre trials. There are finally concerns 
regarding the sham or double blinded nature of the tri-
als. It is difficult to ensure true blinding in these circum-
stances with many of the trials identifying no benefit at all 
Fig. 1  PRISMA flow chart for article selection
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from sham treatment which is unexpected as some placebo 
effect is expected.
PDE5i use prior and during treatment is currently vari-
able. Whilst the majority of studies included a 4-week 
‘washout period’ without PDE5i use, this was not consist-
ent across all studies, with additional variation surrounding 
ongoing PDE5i use and timing of restarting this. Four stud-
ies allowing participants to resume PDE5i use from 1-month 
post-LISWT [2, 17, 20, 21], and one study keeping patients 
on treatment throughout entire treatment duration [18]. 
This is important as this produces as a confounder which 
may explain differences in long-term efficacy post-LISWT. 
Finally, an extremely large variation in administration pro-
tocols was identified. Individual studies varied significantly 
in terms of shockwaves delivered per session, time between 
sessions and even sites of administration as demonstrated in 
Table 1. This presents a limitation towards external validity 
of the studies in view of effect sizes for long-term erectile 
function post-LISWT.
Comment
This systematic review assesses the long-term effect of 
LISWT at over 6 months on vasculogenic ED patients. 
Out of the eleven papers identified, nine demonstrated a 
statistically significant improvement in erectile function at 
6-month follow-up. However, these studies show that beyond 
6 months there is no ongoing improvement in erectile func-
tion seen. Three out of five studies demonstrated a gradual 
decline in erectile function with two showing a plateauing of 
results. However, it is important to note that IIEF-EF scores 
in all studies remained significantly above baseline func-
tional scores, demonstrating benefit even at 12-month post-
treatment. This is likely secondary to the ongoing under-
lying vascular progression of disease, with LISWT having 
no impact on comorbidities or progressive atherosclerotic 
disease affecting the cavernosal tissue [13]. Assessment of 
the overall quality of the evidence for long erectile func-
tion improvement via the GRADE protocol demonstrates 
that current recommendation for use remains low at present 
(Online Resource 3). This is due to the predominantly non-
randomised evidence base currently present with trials pre-
senting small patient numbers, single institutions and meth-
odological concerns regarding the double-blind sham trials.
Subgroup analysis assessing individual cohorts of 
patients for LISWT effectiveness yielded varying results. 
Two studies suggest that younger patients may be more 
likely to benefit from prolonged benefits in erectile func-
tion. This is hypothesised to be secondary to less structural 
cavernosal and ultra-structural damage present, with greater 
VEGF receptor activity resulting in a greater biological 
response from treatment [14, 17]. This has led to sugges-
tions that LISWT may have a role in early intervention, or 
Fig. 2  Long-term efficacy of LISWT based on IIEF-EF scores at baseline, 3, 6 and 12 months
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even prophylactic treatment in high-risk patients, thereby 
preventing irreversible vascular changes [14, 23]. However, 
at present the objective evidence for this is non-existent. 
Similarly, it would be expected that patients with severe ED 
would see a reduced effectiveness of treatment secondary to 
increased ultra-structural damage. Whilst previous findings 
in short-term follow-up have supported this [24], our review 
has identified conflicting evidence in the long term, with 
no clear relationship of ED severity or duration to clinical 
efficacy.
The evidence assessing cardiovascular co-morbidities and 
risk factors on treatment effect in the long term is limited. 
There is contrasting evidence assessing diabetic patients 
with further review certainly needed. Furthermore, whilst 
smoking and presence of other cardiovascular risk factors 
appear to negatively impact the efficacy of treatment, these 
results are restricted to a single study only in the long term 
[20]. Similarly, whilst PDE5i responders and naïve patients 
have previously been identified as positive predictive mark-
ers for treatment success in short term studies [24], this can-
not be determined for long-term studies yet. Only a single 
study demonstrated improved efficacy; however, this was 
not statistically significant. Therefore, at present there is no 
concrete evidence for any subgroup identified as a predictive 
marker for long-term successful treatment.
This is the first review, to our knowledge, to specifically 
assess the long-term efficacy of LISWT for vasculogenic 
ED. It provides important evidence to demonstrate that there 
appears to be a lasting effect of erectile function improve-
ment at 6 months for patients which either plateau or may 
gradually deteriorate towards 12 months post-treatment. 
This is clinically important, providing urologists evidence 
for treatment, but additionally offers evidence for frank dis-
cussion regarding expectations of erectile function beyond 
6-month post-treatment. However, as previously mentioned 
due to varying study methodologies this review highlights to 
researchers further areas of research to increase the evidence 
base surrounding LISWT use.
Whilst there is clinically relevant data currently available, 
there are several concerns regarding current methodology of 
identified trials which require standardisation in future stud-
ies. It is clear larger studies which are multi-institutional and 
multi-national are required in the first instance to increase 
external validity of results. Further to this, PDE5is use prior 
and post-treatment is extremely variable in the literature. 
Whilst a washout period and limited PDE5i use may improve 
the results obtained, it could be argued that future research 
should focus on more real-life applicability by maintenance 
of medical therapy concurrently to LISWT. Additionally, 
future research must standardise administration of LISWT, 
in particular with regard to the device utilised, treatment 
delivery in terms of sessions and duration as well as location 
of administration with current positioning widely varied in 
the studies identified. In terms of outcome measures uti-
lised, there is a need for greater objective parameters through 
penile haemodynamic studies concurrently to subjective 
measures such as IIEF-EF and EHS scores, which can be 
heavily influenced by other factors such as sexual partners, 
lifestyle, life events, psychology and comorbidities [13]. 
Finally, this review has identified a need for longer follow-
up at 12 months and beyond to assess the ongoing longevity 
of treatment efficacy.
As is the case with any systematic review, this review 
has its limitations. These are largely arising from the data 
set available with limitations in the number of trials which 
are available with few randomised studies identified assess-
ing long-term outcomes specifically. Additionally, several 
methodological concerns and variations as previously men-
tioned are present. This is particularly true when consider-
ing treatment administration and concurrent therapy, mean-
ing that generalisability of results must be considered, and 
hence, standardised recommendations could not be made. 
When this variability in methodology was combined with 
the lack of randomised trials reporting standardised outcome 
measures such as IIEF-EF and the large heterogeneity of 
results seen when statistical pooling of randomised studies 
was attempted, meant that any meaningful statistical assess-
ment of data via a meta-analysis was not feasible. Finally, 
there is always the possibility of missed studies which could 
affect current recommendation; however, the risk of this was 
minimised via a comprehensive search strategy and search-
ing both grey and current literature.
Conclusions
This systematic review identifies that LISWT offers a treat-
ment modality which improves erectile function, with results 
lasting to over 6 months. There appears to be some limita-
tion of ongoing benefit beyond this at 12 months with either 
plateauing or even reduction in functional outcomes at this 
time. Increasing age appears to reduce responsiveness to 
LISWT treatment in long-term follow-up studies. Further-
more, ED severity, PDE5i responsiveness and co-morbid-
ities may also influence its effectiveness; however, results 
are inconsistent at present. Whilst LISWT may be a safe 
and acceptable long-term ED treatment modality, it is clear 
further investigation is still needed through larger and more 
standardised trials to improve its evidence base.
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